Vet Pathol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fournel-Fleury, C.
Right arrow Articles by Magnol, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fournel-Fleury, C.
Right arrow Articles by Magnol, J. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Vet Pathol 39:92-109 (2002)
© 2002 American College of Veterinary Pathologists

Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases

C. Fournel-Fleury, F. Ponce, P. Felman, A. Blavier, C. Bonnefont, L. Chabanne, T. Marchal, J. L. Cadore, I. Goy-Thollot, D. Ledieu, I. Ghernati and J. P. Magnol

Laboratoire d'Hématologie-Cytologie-Immunopathologie, Ecole Nationale Vétérinaire de Lyon, France (CF, FP, AB, CB, LC, TM, JLC, IGT, DL, IG, JPM); and Laboratoire d'Hématologie Cellulaire, Centre hospitalier Lyon-Sud, France (PF)


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
The aim of this study is to report 46 new cases of canine T-cell lymphomas among a series of 140 lymphomas studied by immunophenotyping (incidence 32.8%). According to the updated Kiel classification adapted to the canine species, 13 were classified as low-grade and 33 as high-grade lymphomas. Among the low-grade lymphomas, five were small clear-cell lymphomas, three were pleomorphic small-cell lymphomas, and five mycosis fungoides. Among the high-grade cases, there were 11 pleomorphic mixed-, small-, and large-cell lymphomas, 6 pleomorphic large-cell lymphomas, 11 lymphoblastic lymphomas, and 5 unclassifiable high-grade plasmacytoid lymphomas. The cytohistologic features were highly suggestive of a T-cell phenotype on the basis of cell morphology (irregular nuclei and clear cytoplasms) (30/46 cases), a T-cell zone pattern, and the presence of hyperplastic postcapillary venules (22/46 cases). All 46 cases were CD3+ CD79a-, and among 34 cases investigated for CD4 and CD8 expression, 13 were CD4+CD8-, 13 were CD8+CD4-, and 8 were CD4CD8 double positive or double negative. The pleomorphic mixed lymphomas were mainly CD4+CD8- (6/7) and the lymphoblastic lymphomas were double positive or double negative (6/8). The main clinical, hematologic, and biochemical features were generalized (28/46) or regional lymphadenopathy (16/46), hepatosplenomegaly (15/46), extranodal involvement (11/46), mediastinal mass (9/46), and leukemia (8/46), which were mainly present in cases of lymphoblastic lymphomas and hypercalcemia (16/46).

Key words: Canine; classification; immunophenotyping; malignant lymphoma; T-cell lymphoma.

Non-Hodgkin's lymphomas (NHLs), according to human terminology, are common tumors in dogs, whereas Hodgkin's lymphoma has not been recognized yet in this species. Their annual incidence rate was estimated at 33 per 100,000 dogs in the last epidemiologic study of Teske.84 They are highly aggressive,23,28,85 and their etiology remains obscure.36,84 In contrast with similar tumors in cats, no viral cause has been demonstrated, although it has been suggested in the past.68,75,82,88 Moreover, a canine long-term T-cell line, established from a dog with Sézary syndrome, and a canine large granular lymphocyte leukemia, both producing retroviral particles, have been recently reported.26,27

NHLs are also common in humans and are on a noticeable increase.12,15 Given their rate of increase, estimated at 3–10% per annum9,65 at the beginning of the new century, NHLs constitute a significant public health issue. However, NHLs are a group of disparate malignant diseases. The association between a particular environmental cause and the increase in the incidence is now well established in humans for the association of Helicobacter pylori with gastric lymphoma,93,96 the Epstein-Barr virus (EBV) with some Burkitt's and nasal T-cell lymphomas,4,32,33 and the human T-cell lymphotropic virus (HTLV-I) with the adult T-cell leukemia/lymphoma (ATL/L).41,87,92 Thus, in order to provide a plausible explanation for the overall increase, it is important to understand which subgroups are increasing.

The dog, as a close companion of man and submitted to the same environmental influences, has often been proposed as a useful model for studying the etiology and therapy of NHLs.35,54,69,73,83 The value of the canine model nevertheless depends on the possibility of distinguishing the main subgroups in both species using a reliable classification of canine NHLs following the schemes currently used for human lymphomas. The morphologic classifications of canine NHLs have been successively based on different human classifications, e.g., Rappaport,78 working formulation,67 and Kiel classifications.53 The first morphologic studies of canine NHL cells emphasized the rarity of low-grade malignancy lymphomas and, in particular, follicular lymphomas. However, these studies sometimes differ regarding the frequency of occurrence of the different morphological subtypes.1,7,8,19,71

More recently, the immunophenotype has been taken into account, resulting in classifications such as the updated Kiel classification,52 which is based on the fundamental distinction between B-cell and T-cell lymphomas.1,28,51,85 For the veterinary authors, the main difficulties were the standardization of the availability of the different markers for canine lymphoid cells. This standardization came about only recently, in July 1993, during the first Canine Leukocyte Antigen Workshop (CLAW). It demonstrated the availability of accurate T-cell markers (antibodies recognizing the equivalent of the CD3, CD5, CD4, and CD8 molecules)10,14,21,62,80 but not of others, such as F3-20-785 or CA1–4G8,61,85 not truly specific for the T-lineage. Furthermore, no B-cell markers were available except for an antibody against the CD21 molecule61 and for surface (sIg) and cytoplasmic immunoglobulins (cIg).80 As well, there was no true equivalent to the pan-B antibodies used against the CD19 and CD20 molecules in humans. Lately, a monoclonal antibody against the mb1 molecule (CD79a) in humans58 was shown to cross-react with numerous mammalian species, including the dog.43,44 Hence, it has been used as the more reliable pan-B marker in the later studies of canine NHLs.22–24,48 This successive use of various markers, sometimes not readily available, explains the discrepancies between the former results concerning the immunophenotype of canine NHLs, which indicated a high percentage of lymphomas expressing a double (B and T) phenotype,1,28,51 and the latter, which clearly separated B-cell from T-cell lymphomas.23,85 However, Teske and collaborators85 found a high percentage of T-cell lymphomas (37.9%) without any correlation between morphology and immunophenotype, whereas a smaller percentage of T-cell lymphomas (26%) with a morphology clearly suggesting a T-cell immunophenotype was found in a previous study.23

In this article, we set out the incidence and the clinical, morphologic, and immunophenotypic presentation of 46 new cases of canine T-cell lymphomas in comparison with our previous study23 and in the light of the current evolution of the human NHL classifications, i.e., the Revised European American classification of lymphoid neoplasms (REAL)34 and the updated WHO classification.74


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Animals

Among a new series of 140 cases of canine NHLs referred to our laboratory between 1996 and 1999, all studied by immunophenotyping, 46 cases of T-cell lymphomas have been studied. All dogs were evaluated by complete physical, hematologic, and biochemical examination and had not been treated by chemotherapy before the diagnosis.

The diagnosis of malignant lymphomas was based on cytohistologic analysis of fine-needle aspirates (FNA) or imprint smears and biopsy specimens of at least one enlarged lymph node, except in two cases, including one isolated pericardial effusion and one localized intrathoracic infiltration (mediastinal mass and lymph nodes), in which only fine-needle aspirate examination was available. Histologic analysis of extranodal masses, cutaneous biopsies, and cytologic analysis of bone marrow and effusions were selectively performed as well. Immunophenotype was established in all cases by the use of polyclonal antibody against CD3, as pan-T marker, and monoclonal antibody against CD79a, as pan-B marker, on fresh or frozen fine-needle aspirates and paraffin-embedded sections.

Thirty-four cases were evaluated for CD4 and CD8 expression on fresh or frozen cytological preparations (imprint smears, cytocentrifuge preparations of cell suspensions, fine-needle aspirates) and on frozen tissue sections when available.

Fine-needle aspirate and imprint smear evaluation

Cytological smears obtained by fine-needle aspiration (FNA) or imprint of an excised lymph node were air-dried, fixed, and stained by the May–Grünwald–Giemsa (MGG) technique.90

The morphological classification criteria were based on cell size (medium, small, or large, i.e., nucleus equal to, smaller than, or larger than two red blood cells) and on the shape of the nucleus, the density of the chromatin, the presence and aspect of the nucleoli, the extension and basophilia of the cytoplasm, and the mitotic index. The mitotic rate was estimated in cytologic specimens by scanning five fields at 500x and counting mitotic figures. A low mitotic index was defined as 0–1 mitosis/five fields, medium as 2–4/five fields, and high as >=5/five fields. However, regarding the irregular distribution of cell layers on cytologic preparations, the level of mitoses on histology was retained to establish the mitotic rate.

Biopsy specimen evaluation

Biopsy specimens for light-microscopic examination were fixed in 10% neutral buffered formalin at room temperature for 48 hours and processed for routine paraffin-wax embedding. Sections (1.5 µm) were cut and stained with hematoxylin and eosin (HE) and Giemsa. The pattern of the lymphomatous proliferation was noted (diffuse or not) as well as the presence of starry sky, hyperplastic postcapillary venules, and the composition of the background population. The mitotic rate was estimated in histologic specimens by scanning 10 fields at 400x and counting mitotic figures. A low mitotic index was defined as 0–2 mitoses/field, medium as 3–5/field, and high as >=6/field.8

Immunophenotyping

For immunophenotyping by CD3 and CD79a, a standard avidin-biotin immunoperoxidase procedure with Biomeda reagents (AutoProbe II 08–802X; Biomeda, Foster City, CA, USA) was performed. After pretreatment, the slides were covered for 10 minutes with a blocking reagent (tissue conditioner) and then incubated with primary antibodies under the dilution and incubation conditions listed in Table 1. After two rinses in phosphate-buffered saline (PBS), a biotinylated secondary antibody (reagent 1A) preincubated with normal dog serum was applied to each slide for 20 minutes at room temperature. After two washes, streptavidin-peroxidase (reagent 2) was applied for 20 minutes at room temperature. After two rinses in PBS, 3-3'diaminobenzidine was applied for 15 minutes at room temperature as a chromogen (reagent 3). The sections were then washed with distilled water and counterstained with Mayer's haematoxylin. Nonimmune serum was used as a negative control for each specimen. A normal canine lymphoid tissue was used as a positive control. For immunophenotyping by CD4 and CD8, cytological preparations were immediately used or stored at -70C and the lymph node biopsies were frozen in nitrogen-cooled isopentane for the preparation of frozen sections. Immunolabeling was then carried out according to the standard avidin-biotin immunoperoxidase procedure described above but without any pretreatment.


View this table:
[in this window]
[in a new window]
  		Table 1. Antibodies used for immunohistochemical staining of canine lymphomas.

 
Classification

The 46 cases were classified according to the updated Kiel classification with some adaptations, taking into account morphologic types not included in the human classification as previously described.23


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Incidence, morphology, and immunophenotyping

The total incidence of T-cell lymphomas over this period of 4 years was 32.8% (46/140). The respective incidence of the various subtypes of the updated Kiel classification adapted to the canine species is listed in Table 2. Thirteen of these lymphomas (28.3%) were classified as low-grade lymphomas and 33 (71.7%) as high-grade lymphomas.


View this table:
[in this window]
[in a new window]
  		Table 2. Updated Kiel classification of the 46 canine T-cell lymphomas: possible correlations with the REAL classification.

 
Among the low-grade lymphomas, eight (17.4%) belonged to the category of small-cell lymphomas, 5 (10.9%) of these being small, clear-cell lymphomas and three (6.5%) being pleomorphic small-cell lymphomas. Five (10.9%) were mycosis fungoides.

Among the 33 lymphomas classified as high grade, 11 (23.9%) were pleomorphic mixed-, small-, and large-cell lymphomas, 6 (13.0%) were pleomorphic large cells, 11 (23.9%) were lymphoblastic, and 5 (10.9%) were unclassifiable high-grade plasmacytoid lymphomas.

All 46 cases expressed a CD3+ CD79a- phenotype. Among the 34 cases evaluated for CD4 and CD8 expression, 13 were CD8+CD4-, 13 were CD4+ CD8-, 5 were CD4+ CD8+, and 3 were CD4- CD8-.

The main cytologic, histologic, and immunologic features of each type (Tables 3, 4) were as follows:

Regarding all subtypes, the most frequent and striking morphologic criteria were constituted by hyperplastic postcapillary venules (22/46) except in lymphoblastic lymphomas, irregular nuclei and pale cytoplasms (30/46) except in unclassifiable high-grade plasmacytoid lymphomas, and frequent residual plasma cells in the background displaying the normal residual B maturation.


View this table:
[in this window]
[in a new window]
  		Table 3. Morphology of the various subtypes of canine T-cell lymphomas.

 

View this table:
[in this window]
[in a new window]
  		Table 4. Incidence of expression of CD4 and CD8 markers in canine lymphomas with morphological subtypes.

 


View larger version (174K):
[in this window]
[in a new window]
  		Fig. 1. Mycosis fungoides. Large granular lymphocyte type. FNA. Note cytoplasmic azurophilic granules and some cleaved, more or less convoluted nuclei. MGG. Bar = 10 µm.
Fig. 2. Mycosis fungoides (patch stage). Tissue section. Epidermis is infiltrated by neoplastic cells with nuclei varying from round to reniform and abundant, pale eosonophilic cytoplasm with poorly defined cell boundaries (Pautrier's microabcesses). HE. Bar = 40 µm.
Fig. 3. Small clear cell type. FNA. Small cells with round or sometimes irregular nuclei, irregularly aggregated chromatin, prominent nucleoli, and projecting, uni- or bipolar, clear cytoplasm. MGG. Bar = 10 µm.
Fig. 4. Small clear cell type. Tissue section. Note the round nuclei with irregularly aggregated chromatin. The extended pale cytoplasm is visible but less obvious than on FNA. HE. Bar = 10 µm.
Fig. 5. Small clear cell type. Tissue section. Characteristic paracortical or T-zone pattern with numerous normal residual B-follicles. HE. Bar = 400 µm.
Fig. 6. Small clear cell type. Tissue section. Hyperplastic postcapillary venules. HE. Bar = 25 µm.

 


View larger version (167K):
[in this window]
[in a new window]
  		Fig. 7. Pleomorphic small-cell type. FNA. Small cells with irregular nuclear outlines. Note the scant, pale cytoplasm. MGG. Bar = 10 µm.
Fig. 8. Pleomorphic small-cell type. Tissue section. The histological aspect is very similar to the cytological one, especially the size and the very irregular nuclear outlines of the lymphomatous cells. Nucleoli are more obvious than on FNA. HE. Bar = 10 µm.
Fig. 9. Mixed pleomorphic, small- and large-cell type. FNA. Mixing of small, medium-sized, and large cells, all characterized by irregular outlines and pale cytoplasm. Note the nucleoli more obvious in the largest cells. MGG. Bar = 10 µm.
Fig. 10. Mixed pleomorphic, small- and large-cell type. Tissue section. Note the striking irregular nuclear outlines, the abundant pale cytoplasm, and the various sizes. HE. Bar = 10 µm.
Fig. 11. Pleomorphic large-cell type. FNA. Note the striking irregular nuclear outlines, fine chromatin, frequent visible nucleoli, and abundant pale cytoplasm. MGG. Bar = 10 µm.
Fig. 12. Pleomorphic large-cell type. Tissue section. Irregular nuclear outlines, numerous nucleoli, and irregularly distributed pale cytoplasm are remarkable in the largest cells. HE. Bar = 10 µm.

 


View larger version (171K):
[in this window]
[in a new window]
  		Fig. 13. Lymphoblastic type. FNA. Characteristic aspect of medium-sized cells with fine, dusty chromatin, poorly visible nucleoli, and small amount of moderately basophilic cytoplasm. Two bulb-shaped cells and a cell in metaphase. MGG. Bar = 10 µm.
Fig. 14. Lymphoblastic lymphoma. Tissue section. Homogeneous proliferation of medium-sized cells with round or convoluted nuclei, dusty chromatin, and inconspicuous nucleoli. Giemsa. Bar = 10 µm.
Fig. 15. Unclassifiable high-grade plasmacytoid type. FNA. Small, medium-sized, and large cells, with extended, deeply basophilic cytoplasm. One binucleated cell in the field. In this example, the lymphomatous cells exhibit fine chromatin and prominent nucleoli. MGG. Bar = 10 µm.
Fig. 16. Unclassifiable high-grade plasmacytoid type. FNA. Note the irregularly clumped chromatin and the less visible nucleoli. One binucleated lymphomatous cell and a normal residual plasma cell in the center of the field. MGG. Bar = 10 µm.
Fig. 17. Unclassifiable high-grade plasmacytoid type. Tissue section. Same case as in Fig. 16. Note the high mitotic index and the binucleated cell in the center of the field. HE. Bar = 25 µm.
Fig. 18. Unclassified high-grade plasmacytoid type. Tissue section. Higher magnification of Fig. 17. HE. Bar = 10 µm.

 
Epidemiologic, clinical, and biological features

The main results are listed in Table 5.


View this table:
[in this window]
[in a new window]
  		Table 5. Clinical and biological features of canine T-cell lymphomas according to the different morphological subtypes.

 
T-cell lymphomas occurred in animals from 1 to 12 years old, with a median age of 6.9. The sex ratio of males in relation to females was 1.37 for a reference population of 1.04. A breed predilection was found for boxers only (15/46).

The animals were referred for lethargy, weakness, weight loss, peripheral lymph node enlargement, cutaneous disease, and polyuria-polydipsia of variable duration. Time before establishment of diagnosis was longest (several months) for MF and small clear cell lymphoma cases. At the time of diagnosis, the most common finding was a generalized lymphadenopathy (28/46). A regional lymphadenopathy was found in 16/46 cases.

Hepatosplenomegaly occurred in 15/48 cases and mainly in the high-grade subtypes. A mediastinal mass was found in 9/46 cases, mainly in cases of lymphoblastic lymphomas (6/11) and in 3 cases (3/5) of unclassifiable high-grade plasmacytoid lymphomas. Extranodal involvement occurred in 11/46 cases. The skin was involved in six cases (5/5 mycosis fungoides, 1 pleomorphic large cell lymphoma), coelomic cavity in the form of effusion in three cases, bone in one case of unclassifiable high-grade plasmacytoid lymphoma, and the nasal cavities in one case of pleomorphic small-cell lymphoma.

Blood cytopenias, in term of anemia and/or thrombocytopenia, occurred in 16/46 cases. Leukemia, characterized by involvement of bone marrow and blood, occurred in the course of the disease in 8/46 cases, mainly in lymphoblastic lymphomas (6/11 cases) and in two cases (2/5) of unclassifiable high-grade plasmacytoid lymphomas.

Biochemical profile was generally unremarkable except for evidence of hypercalcemia in 16/46 cases without correlation either to a particular subtype (see Table 5) or to a particular clinical presentation. However, hypercalcemia was never found in mycosis fungoides and small clear-cell lymphomas.


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Determination of the immunophenotype of malignant lymphomas in humans has become an essential step in their classification because of the relation to biological behavior and response to therapy. Consequently, the updated Kiel,52 REAL,34 and WHO74 classifications all differentiate lymphomas based on immunophenotype. The most recent statistical studies carried out on a high number of cases estimate the frequency of human T-cell lymphomas in Europe and in the USA at 12% of cases.86 In Japan, this frequency is much greater (around 50%) given the particular incidence of adult T-cell lymphoma/leukemia (ATL/L) associated with HTLV-I.87 As the standardization of the specificities of the different antibodies is relatively recent,14 very few studies in dogs differentiate between T- and B-cell lymphomas.

Indeed, only two studies considering the immunophenotype on a significant number of cases are published, showing 37.9%85 and 26%23 of T-cell lymphomas. In this article, the incidence of canine T-cell lymphomas (32.8%) appears slightly higher than in our previous study (26%).23 This percentage of 32.8% is closer to those of Teske (37.9%).85 In that study, however, the use of antibodies such as F3.20.755 or CA1-4G8,61 which are not truly specific for the T-lineage,10,14 may be responsible for an overestimation of T-lymphomas. Nonetheless, these percentages are clearly higher than that of T-cell lymphomas in humans outside of Japan. It is obvious that several additional studies of numerous cases91 are necessary to fully establish the percentage of T-lymphomas in the dog. If such a frequency of T-cell lymphomas in the dog is confirmed in the future, it would raise the question of a possible incidence of one or several environmental agents on T-cell neoplasia development. In human medicine, it is well established that the adult T-cell lymphoma/leukemia is associated with infection by HTLV-I41,89 and the nasal T-cell lymphomas with the Epstein-Barr virus. The association with the Epstein-Barr virus is also suspected for angioimmunoblastic T-cell lymphomas.33,46,95 Until now, no retrovirus has been demonstrated to be associated with lymphomas in the dog. Recently, the finding of canine T-cell neoplasias producing retroviral particles,26,27 however, suggests the involvement of virus in canine T-cell lymphomagenesis.

Besides the global incidence of T-cell lymphomas, the relative frequency of the different subtypes is important to consider. In our present study, the most frequent subtypes are the pleomorphic mixed and the lymphoblastic lymphomas. The updated Kiel classification now separates the pleomorphic low-grade small-cell lymphomas from the high-grade mixed- and large-cell pleomorphic lymphomas. However, the pleomorphic lymphomas fall into the same category as the unspecified peripheral T-cell lymphomas of the REAL and the upcoming WHO classifications (Table 6). By gathering all the pleomorphic lymphomas in our study, they could constitute a major category within the T-cell lymphomas in the dog (43.5%). This would be in agreement with Teske et al. and with our previous study and also with current human data (around 58% of T-NHLs).74,86


View this table:
[in this window]
[in a new window]
  		Table 6. Comparison between REAL (34) and UPDATED WHO (74) classifications of human non-Hodgkin's lymphoid tumors.

 
The proportion of lymphoblastic lymphomas seems to be clearly higher (11/46, 23.9%) than found in our previous study (1/24, 4.2%) and in all previous veterinary studies performed with or without determination of immunophenotype28,85 except Carter's (49/285, 17.2%).8 It is close to the percentage of human adult T-lymphoblastic lymphomas (around 17% of the T-NHLs).81 The average age (5.3 years) of the affected animals does not allow any comparison with the incidence of lymphoblastic lymphomas in children. In terms of incidence, among the other categories of T-cell lymphomas, the high-grade unclassifiable plasmacytoid lymphomas, the small clear-cell lymphomas and the mycosis fungoides remain less frequent, as in our previous study.

Regarding the classification of various morphological subtypes, it is important to notice that, as in human medicine, the classification of all lymphomas including T-cell types is constantly developing. The updated Kiel classification52 was the first human system based on immunophenotype and morphology separating low-grade from high-grade lymphomas without full reference to the worse prognosis for T-cell lymphomas.17 Further classifications were based on histologic, immunologic, and genetic features of the different entities, on their clinical presentation and course and postulated normal counterpart in the immune system. The different categories of T-cell neoplasias that have been defined by the REAL classification34 and the updated WHO classification project74 are very similar and are shown in Table 6. Despite the obvious clinicopathologic interest of these new classifications, the lack of sufficient epidemiologic, phenotypic, and genetic information in dogs causes difficulties in adapting these classifications. Thus, we have chosen to use the updated Kiel classification to first compare the morphologic characteristics of canine T-cell lymphomas to those of the various subtypes of human T-cell lymphomas and then to try a comparison with the main categories of the new classifications. In this article, the general morphologic appearance of T-cell lymphomas shows great similarities with our previous study.23 This confirms, on the whole, the good correlation between morphology and immunophenotype. This should allow the pathologist to suspect a T-phenotype by cytohistologic analysis in dogs just as it is possible in humans, except for lymphoblastic and unclassifiable high-grade plasmacytoid lymphomas, even if the immunophenotyping appears absolutely necessary to classify the lymphoma as a B- or a T-cell one. On the architectural level, since T-cell lymphomas are generally diffuse, the T-cell zone pattern is suggestive of phenotype in small clear-cell lymphomas along with the presence of microvascular hyperplasia seen in 47.8% of all T-cell lymphoma cases in all subtypes, except in lymphoblastic lymphomas. Cytologic criteria suggestive of T-phenotype either on cytologic or histologic examination are irregular nuclear outlines, abundant pale cytoplasm sometimes containing azurophilic granules, and a background of normal plasma cells. These observations contrast with those of Teske and collaborators, who did not find any correlation between morphology and immunophenotype except for the presence of numerous plasma cells in canine T-cell lymphomas.85 This difference may be explained by the fact that the use of some nonspecific T-cell markers led to an incorrect interpretation of the morphologic data for the whole study. These correlations between morphology and phenotype are in agreement with those observed in human medicine on the basis of very similar morphologic criteria. 20,39,40,42,52,81 Regarding the various subtypes of T-cell lymphomas, it is possible to emphasize some morphologic characteristics in order to try a comparison with the different categories of human T-cell lymphomas.

Histologic lesions of mycosis fungoide cases are similar on the whole to those described in previous veterinary studies and in the human species.18,40,42,57,60,81 However, it is important to point out the loss of epidermotropism and the possible transformation toward a high-grade type in advanced stages, like in humans, leading to some difficulties of classification between cutaneous T-cell lymphomas and mycosis fungoides.79,81 For this reason, the cytologic criteria, either in cytology or in histology, i.e., cerebriform or convoluted nuclei and large granular lymphocyte aspect particularly obvious on FNA, seem important to consider concomitantly.23,25,26,57

The category of small clear-cell lymphomas, very suggestive of a T-phenotype because of its characteristic extended, frequently unipolar pale cytoplasm and its T-cell zone pattern, has no definite equivalent with any small T-cell lymphoma in humans. It can be compared, on the one hand, with the T-zone lymphoma of the Kiel classification on the basis of its histologic pattern, but it appears cytologically different from this latter, which mixes numerous small monomorphic and pleomorphic cells and T-immunoblasts. It could be similar to the T-prolymphocytic lymphoma/leukemia (T-PLL) of the Kiel, REAL, and WHO classifications on the basis of the presence in some cells of a clearly visible nucleolus and of a frequent T-cell zone pattern as in human T-PLL. However, it is very important to emphasize the noticeable difference, which is the lack of rapid and progressive leukemia in the small clear-cell lymphomas in dogs compared with the T-PLL in humans. Moreover, in our previous study, we found two cases of T-prolymphocytic lymphomas, which may constitute another rare category of small T-cell lymphomas in the dog, closer to the human T-PLL.

The category of pleomorphic small-cell lymphomas, which is in the minority, may first be compared with that of the Kiel classification,52,81 as has been done in Teske's study85 and in our previous study,23 or to the small-cell types of the unspecified peripheral T-cell lymphomas of the REAL and the updated WHO classifications, which group all the pleomorphic lymphomas.

In the same way, the mixed- and large-cell pleomorphic NHLs show characteristics similar to the corresponding categories of the Kiel classification and of the unspecified peripheral T-cell lymphomas of the REAL and the updated WHO classifications, i.e., the various cellular sizes, the great nuclear irregularity, ranging from slightly indented to serrated to cerebriform, and the abundant pale cytoplasm encountered in some of these lymphomas in humans.2,40

In theory, lymphoblastic T-cell lymphomas are morphologically difficult to distinguish from their B-equivalents. But, in practice, the presumption of a T-phenotype in lymphoblastic lymphomas is high. The reasons are that all the lymphoblastic lymphomas among the 140 cases of lymphomas that have been morphologically and phenotypically reviewed for this study have a T-phenotype, as does the only lymphoblastic lymphoma of our previous study. If future studies confirm this, it will be in agreement with human data, where 90% of lymphoblastic lymphomas have a T-phenotype.5,66 From a morphologic point of view, canine lymphoblastic lymphomas appear very similar to their human equivalents.

Only the unclassifiable high-grade plasmacytoid lymphomas constitute a real problem for the morphologic presumption of a T-phenotype since they consist of small, medium-sized, or large blast cells with highly nucleolated nuclei and hyperbasophilic, often plasmacytoid, cytoplasm. The main criteria suggesting a T-phenotype are the presence of some irregular nuclei among the whole population and of normal plasma cells in the background and especially the lack of the various cell components of the polymorphic centroblastic B-cell lymphomas.23 These unclassifiable high-grade plasmacytoid lymphomas cannot be morphologically compared with any particular category of human T-cell lymphomas but may constitute, in the future, a subtype of the peripheral T-cell lymphomas unspecified of the REAL and the WHO classifications.

Finally, the histologic study in this series did not reveal particular entities like angiocentric, angioimmunoblastic, and anaplastic large-cell lymphomas, which constitute separate entities in humans.

The precise determination of the immunophenotype is essential to identify the various categories of human lymphomas of the most recent classifications (REAL, updated WHO). The main markers, used in human medicine6,11,16,29,37,38,39,49,92,94 for the precise determination of the immunophenotype of T-cell neoplasms are antibodies against pan-T antigens (CD2, CD3, CD5, CD7), which permit identification of a T-phenotype; antigens restricted to the cortical thymocytes (CD1) or present on the immature lymphoid cells, like the terminal deoxynucleotidyl transferase (TdT) expressed by the lymphoblastic lymphomas (typically CD1+ TdT+); antigens defining functional subpopulations (CD4, CD8) mono-expressed by the lymphomas originating from the peripheral T-cells (CD4+CD8- or CD8+ CD4-) and nonexpressed or, on the opposite, coexpressed by the immature cells of lymphoblastic lymphomas (CD4+CD8+ or CD4-CD8-); specific antigens of T-cell receptor, TCR ({alpha} ß) or TCR ({gamma} {delta}), the majority of peripheral T-lymphocytes belonging to the {alpha} ß subset, whereas only a minority being {gamma} {delta} T-cells (these latter antigens allow the identification of some rare entities like hepatosplenic {gamma} {delta} T-cell lymphomas,34,59,74,81); antigens present in the azurophilic granules of cytotoxic cells such as the perforin and the TiA1 protein expressed by the T cytotoxic cell (T CD8+) and natural killer (NK) lymphomas; and finally, activating antigens as the CD30 expressed by the anaplasic large-cell lymphomas (CD30+). In addition to these general considerations, it is important to point out that some categories of T-cell lymphomas in humans more specifically express certain markers, like the mycosis fungoides, which are essentially CD4+, the unspecified pleomorphic lymphomas, which more often have a CD4+ phenotype, than a CD8+ phenotype, and the adult T-cell lymphoma/leukemia, which are usually CD4+. Conversely, they could also lose expression of some pan-T markers.

Therefore, phenotypic heterogeneity of human T-cell lymphomas is remarkable and as such contributes to the diagnosis of T-cell lymphoma subcategories. Unfortunately, the panel of monoclonal and polyclonal antibodies available for the identification of these markers in the dog is still incomplete. Among T-markers, the equivalents of CD3, CD5, CD4, and CD8 molecules, recognized by the corresponding heterospecific or homospecific antibodies, seem to be well established.

Some antibodies against the CD1a molecule recognizing dendritic and Langerhans cells and some cortical thymocytes have been reported in the dog,63 but their expression in canine lymphoblastic lymphomas has not been reported. In addition, we do not have any reference concerning the possible cross-reactivities between canine and human antibodies against the TdT, the CD30 molecule, and the TiA1. A cross-reactivity against the perforin of the large granular lymphoma cells has been reported in the feline species45,50 but not, to our knowledge, in the canine species. In our study, we used the anti-CD3 and the anti-CD79a antibodies to determine the T-immunophenotype (CD3+CD79a-) expressed by all T-lymphomas, lymphoblastic lymphomas included. The expression of CD4 and CD8 markers seems to be approximately equivalent between CD8+CD4- and CD4+CD8- lymphomas. There are, however, noticeable differences between the various categories of lymphomas. Canine mycosis fungoides are all CD8+, which is in agreement with most veterinary observations23,57,60 but differs with human data. The pleomorphic mixed-, small-, and large-cell lymphomas appear mainly CD4+CD8- (85.7%). This agrees with the mature T-cell phenotype most frequently expressed by the human unspecified peripheral T-cell lymphomas (PTCLs). The lymphoblastic lymphomas usually express an immature double negative or double positive phenotype (75%), like in the human lymphoblastic lymphomas, which are CD4+CD8+ or CD4-CD8- in 80% of cases.5,6,49,81 Finally, the phenotype of the unclassifiable high-grade plasmacytoid lymphomas, mainly CD8+ (CD8+CD4- in 60% of cases, CD8+CD4+ in 40% of cases) but never, until now, CD4+CD8-, constitutes an additional argument to consider them as a particular entity.

From a clinical point of view, peripheral T-cell lymphomas (PTCLs) in humans are clearly distinguished from lymphoblastic lymphomas originating from precursor T-cells. The clinical presentation of the PTCLs is very polymorphous, making the diagnosis sometimes very difficult.20 According to a recent study concerning one of the largest series of lymphomas,2 it has been established that a majority of these affect medium-aged adults (on average, 53 years), with a slight predominance of males.2 A generalized lymphadenopathy, sometimes with moderately enlarged lymph nodes, predominates (68%) and, to a lesser extent, an extranodal invasion (37%), the presence of a mediastinal mass (32%), and bone marrow involvement (25%). The lymphoblastic lymphomas mainly affect children and young adults but may arise at any time and twice as much in men as in women.64,81 They are generally characterized by a mediastinal mass (57–75%) and the frequent presence of acute leukemia (40–72%). To our knowledge, no study has, up to now, established the epidemiologic and clinical particularities of the T-lymphomas in dogs. The current veterinary data concern all the lymphomas without reference to the phenotype. In our study, the average age (6.9 years) of the dogs affected by a T-cell lymphoma does not show any difference with the one (from 6.3 to 7.7 years) from the previous veterinary studies3,31,54,70,72,84 and may be compared with the human T-lymphomas data. However, a slight difference of the average age seems to appear between low-grade and high-grade lymphomas, the lymphomas affecting the youngest animals being the unclassifiable high-grade plasmacytoid and lymphoblastic lymphomas and the oldest animals being affected by the mycosis fungoides. Contrary to human medicine but in agreement with most of the previous veterinary data,3,31,84 there appears to be no sex predilection for the canine T-cell lymphomas in our study. Finally, with respect to the general canine lymphoma data,3,76,77,84 the overrepresentation of boxers is in agreement with the preestablished data.

The predominating clinical presentation of generalized lymphadenopathy agrees with the general data in canine lymphomas and with the incidence of disseminated forms (stage III–IV) in human T-cell lymphomas. However, the presentation of regional lymph node enlargement, sometimes of small volume (34.8%), must be emphasized since it could constitute, as in humans, a pitfall for early diagnosis. Overall, the frequency of extranodal involvement (23.9%) appears lower than in human T-lymphomas (37.1%) and is largely due to the cutaneous involvement in mycosis fungoides cases. In our series, only one case of bone disorder and one of nasal involvement were encountered. This last case, nonangiocentric at histologic examination, may not be compared with the angiocentric nasal type of the recent REAL and upcoming WHO classifications. This extranodal involvement could be underestimated since extranodal atypical T-cell lymphomas may not be recognized by veterinary clinicians and may not be referred to diagnostic centers. The incidence of a mediastinal mass appears rather low (19.6%) in our study. It is, however, frequent in the unclassifiable high-grade plasmacytoid lymphomas (3/5, 60%) and in lymphoblastic lymphomas (6/11, 54.5%), which agrees with the observation of Carter and collaborators8 and with the human data.81

Leukemia is only found in the unclassifiable high-grade plasmacytoid lymphomas (2/5, 40%) and especially in the lymphoblastic lymphomas (6/11, 54.5%), which is also in line with the observation of Carter and collaborators8 and with the human data.

The other hematologic and biochemical data are not remarkable compared with the general data concerning the canine lymphomas56 except for the incidence of hypercalcemia (34.8%). This value comes close to the highest percentages of the previous veterinary studies (range 10–40%)13,54 and confirms the association between hypercalcemia and T-cell lymphomas in dogs, which has already been pointed out by other authors.28,84,92 In humans, hypercalcemia is much more common in HTLV-I-associated leukemia/lymphomas.30,34,47

This study showed that gathering all the morphologic, phenotypic, and clinical data during this study might allow identification of new entities and comparison with the human REAL and updated WHO new classifications since these latter consider all the previous data and give up the classification of lymphomas of low and high grade, formerly carried out on the morphologic criteria alone.

According to these criteria, the precursor T-lymphoblastic lymphomas with rapid evolution, affecting dogs of a lower average age, showing frequent leukemic and mediastinal invasions, and characterized by monotonous proliferations of medium-sized cells with a fine chromatin and inconspicuous nucleoli, often double-negative or double-positive CD4CD8, may easily be compared with their human equivalents and seem to be much more frequent than their B-equivalents.

Mycosis fungoides, affecting old animals, now seem to be clearly defined in dogs on the basis of clinical, cytohistologic, and phenotypic data, i.e., skin erythema, ulcers or nodules, epitheliotropism, cleaved or convoluted nuclei, sometimes azurophilic cytoplasmic granules, and, in a majority, a CD8+ phenotype.

The small clear-cell lymphomas evolving slowly and affecting adult or old animals, characterized by an extended unipolar pale cytoplasm and a T-cell zone pattern nonassociated with leukemia, constitute for us a special category of small T-cell lymphomas.

The pleomorphic lymphomas, which predominate in this study, affect middle-aged dogs with a generalized or localized lymphadenopathy and have a diffuse infiltration of small, medium-sized, or large cells with irregular nucleus and clear cytoplasm. They express a phenotype of peripheral T-cells, more often CD4+. These lymphomas should be regrouped in a peripheral T-cell lymphoma unspecified category until categorization of specific variants occurs.

The category of unclassifiable high-grade plasmacytoid lymphomas remains mysterious and needs to be confirmed as a specific entity. In this case, it should define a category of aggressive lymphomas affecting mainly young adults with an occasionally mediastinal and leukemic presentation, a particular plasmacytoid morphology, and a mostly CD8+ phenotype.

To determine the incidence as well as the evolution of the various categories of canine T-cell lymphomas, it is essential to conduct further epidemiologic and statistical studies and to investigate the possible influence of environmental agents on the development of different categories of canine T-cell lymphomas.


   Acknowledgments
 
The authors thank F. Pizzhighini and S. Balleydier for technical assistance, M. Meyer for preparing the manuscript, and M. F. Perron for correcting the manuscript.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Appelbaum FR, Sale GE, Storb R, Charrier K, Deeg HJ, Graham T, Wulff JC: Phenotyping of canine lymphoma with monoclonal antibodies directed against cell surface antigens: classification, morphology, clinical presentation, and response to chemotherapy. Haematol Oncol 2:151-158, 1984[Medline]
  2. Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, De Vivo A, Piccioli M, Fraternali Orcioni G, Pieri F, Goldoni A, Piccaluga PP, Zallocco D, Burnelli R, Leoncini L, Falini B, Tura S, Pileri SA: Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Annals of Oncol 8:583-592, 1997[Abstract/Free Full Text]
  3. Bäckgren AW: Lymphatic leukosis in dogs. An epizootological clinical and haematological study. Acta Vet Scand 6:(Suppl 1) 7-80, 1965
  4. Ballerini P, Gaidano G, Gong J, Tassi V, Saglio G, Knowles D, Dalla-Favera R: Multiple genetic lesions in AIDS-related non-Hodgkin lymphoma. Blood 81:166, 1993[Abstract/Free Full Text]
  5. Bernard A, Boumsell L, Reinherz L: Cell surface characterization of malignant T-cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T-cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphomas. Blood 57:1105-1113, 1981[Abstract/Free Full Text]
  6. Brenner MB, McLean J, Scheft M, Warnke RA, Jones N, Strominger JL: Characterization and expression of the human ß T-cell receptor using a framework monoclonal antibody. J Immunol 138:1502-1507, 1987[Abstract]
  7. Carter RF, Valli VEO: Advances in the cytologic diagnosis of canine lymphoma. Semin Vet Med surg (Small Anim) 3:167-175, 1988
  8. Carter RF, Valli VEO, Lumsden JH: The cytology, histology and prevalence of cell types in canine lymphoma classified according the National Cancer Institute Working Formulation. Can J Vet Res 50:154-164, 1986[Medline]
  9. Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, De Sanjose S, Tumino R, Vornanen M: The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627-633, 1999
  10. Chabanne L, Marchal T, Kaplanski C, Fournel-Fleury C, Magnol JP, Monier JC, Rigal D: Screening of 78 monoclonal antibodies directed against human leukocyte antigens for cross-reactivity with surface markers on canine lymphocytes. Tissue Antigens 43:202-205, 1994[Medline]
  11. Chadburn A, Knowles DM: Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non Hodgkin's lymphomas. Am J Clin Pathol 102:284-291, 1994[Medline]
  12. Chassagne-Ckément C, Blay JY, Treilleux I, Sebban C, Bergeron C, Biron P, Philip T: Epidémiologie des lymphomes malins non hodgkiniens: données actualisées. Bull Cancer 86:529-536, 1999[Medline]
  13. Chew DJ, Meuten DJ: Disorders of calcium and phosphorus metabolism. Vet Clin North Am 12:411-438, 1982
  14. Cobbold SP, Metcalfe S: Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 43:137-154, 1994[Medline]
  15. Coiffier B: Lymphomes malin non-Hodgkiniens. Rev Prat Paris 43:1615-1616, 1993
  16. Coiffier B, Berger F, Bryon PA, Magaud JP: T-cell lymphomas: immunologic, histologic, clinical and therapeutic analysis of 63 cases. J Clin Oncol 6:1584-1591, 1988[Abstract/Free Full Text]
  17. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J, for the GELA (Groupe d'Etude des Lymphomes Agressives): Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Annals Oncol 1:45-50, 1990[Abstract/Free Full Text]
  18. Day MJ: Immunophenotypic characterization of cutaneous lymphoid neoplasia in the dog and cat. J Comp Pathol 112:79-96, 1995[CrossRef][Medline]
  19. Delverdier M, Buchet M, van Haverbeke G: Histologie et cytologie des lymphomes malins canins. Etude comparative des classifications actuelles. Rev Med Vet 139:1141-1150, 1988
  20. Felman P, Gentilhomme O: Atlas de Cytopathologie Ganglionnaire. Arnette, Paris, France 1997
  21. Ferrer L, Fondevila D, Rabanal R, Ramis A: Detection of T lymphocytes in canine tissue embedded in paraffin wax by means of antibody to CD3 antigen. J Comp Pathol 106:311-314, 1992[CrossRef][Medline]
  22. Fisher DJ, Naydan D, Werner LL, Moore PF: Immunophenotyping lymphomas in dogs: a comparison of results from fine needle aspirate and needle biopsy samples. Vet Clin Pathol 24:118-123, 1995[Medline]
  23. Fournel-Fleury C, Magnol JP, Bricaire P, Marchal T, Chabanne L, Delverdier A, Bryon PA, Felman P: Cytohistological and immunological classification of canine malignant lymphomas. Comparison with human non-Hodgkin's lymphomas. J Comp Pathol 117:35-39, 1997[CrossRef][Medline]
  24. Fournel-Fleury C, Magnol JP, Chabanne L, Ghernati I, Marchal T, Bonnefont C, Bryon PA, Felman P: Growth fractions in canine non-Hodgkin's lymphomas as determined in situ by the expression of the Ki-67 antigen. J Comp Pathol 117:61-72, 1997[CrossRef][Medline]
  25. Fournel-Fleury C, Magnol JP, Guelfi JF: Atlas en Couleur de Cytologie du Cancer chez le Chien et le Chat/Color Atlas of Cancer Cytology of the Dog and Cat. Pratique Médicale et Chirurgicale de l'Animal de Compagnie, Paris, France 1994
  26. Ghernati I, Auger C, Chabanne L, Corbin A, Bonnefont C, Magnol JP, Fournel C, Rivoire A, Monier JC, Rigal D: Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sézary syndrome and producing retroviral particles. Leuk 13:1281-1290, 1999
  27. Ghernati I, Corbin A, Chabanne L, Auger C, Magnol JP, Fournel C, Monier JC, Darlix JL, Rigal D: Canine large granular lymphocyte leukemia and its derived cell line produce infectious retroviral particles. Vet Pathol 37:4310-317, 2000[Abstract/Free Full Text]
  28. Greenlee PG, Filippa DA, Quimby F, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI: Lymphomas in dogs. A morphologic, immunologic and clinical study. Cancer 66:480-490, 1990[CrossRef][Medline]
  29. Grogan TM, Fielder K, Rangel C, Jolley CJ, Wirt DP, Hicks MJ, Miller TP, Brooks R, Greenberger B, Jones S: Peripheral T-cell lymphomas aggressive disease with heterogeneous immunotypes. Am J Pathol 120:356-370, 1985[Abstract]
  30. Grossman B, Schechter GP, Horton JE, Pierce L, Jaffe E, Whal L: Hypercalcemia associated with T-cell lymphoma-leukemia. Am J Clin Pathol 75:149-155, 1981[Medline]
  31. Haga T, Yokomori K, Nakayama H, Hayashi T, Goto N, Takahashi R, Fujiwara K: Canine and feline lymphoid and myeloid tumors encountered in Tokyo. Jpn J Vet Sci 50:809-813, 1988
  32. Hamilton-Dutoit S, Pallesen G, Franzmann M, Karkov J, Black F, Skinhoj P, Pedersen C: AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 138:149-163, 1991[Abstract]
  33. Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S: Nasal T-cell lymphoma casually associated with Epstein-Barr virus. Clinicopathologic, phenotypic and genotypic studies. Cancer 77:2137-2149, 1996[CrossRef][Medline]
  34. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Woolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Mueller-Hermeling HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European–American classification of lymphoid neoplasms: a proposal from the international study group. Blood 84:1361-1392, 1994[Free Full Text]
  35. Hayes HM: The comparative epidemiology of selected neoplasms between dogs, cats and humans. A review. Eur J Cancer 14:1299-1308, 1978
  36. Hayes HM, Tarone RE, Cantor KP, Jessen CR, Mac Curnin DM, Richardson RC: Case–control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 83:1226-1231, 1991[Abstract/Free Full Text]
  37. Henni T, Gaulard PH, Divine M: Comparison of genetic probe with immunophenotypic analysis in lymphoproliferative disorders: a study of 87 cases. Blood 72:1937-1942, 1988[Abstract/Free Full Text]
  38. Horning SJ, Weiss LM, Crabtree GS, Warnke RA: Clinical and phenotypic diversity of T-cell lymphomas. Blood 67:1578-1590, 1986[Abstract/Free Full Text]
  39. Jaffe ES: Hematopathology: integration of morphologic features and biologic markers for diagnosis. Mod Pathol 12:109-115, 1999[Medline]
  40. Jaffe ES: Surgical Pathology of the Lymph Nodes and Related Organs, 2nd ed. PA Saunders, Philadelphia, PA 1995
  41. Jaffe E, Blattner W, Blayney D, Bunn P, Cossman J, Robert-Guroff M, Gallo R: The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Am J Surg Pathol 8:263-275, 1984[Medline]
  42. Jaffe ES, Krenacs L, Raffeld M: Classification of T-cell and NK-cell neoplasms based on the REAL classification. Annals of Oncol 8:(Suppl 2) S17-S24, 1997
  43. Jones M: Peptide Immunisation as a Source of Cross-species Reactive Antisera Recognizing Leukocyte Differentiation Antigens. Immunological Reagents for the Study of Disease in Companion Animals. The Wellcome Trust, London, UK 1993
  44. Jones M, Cordell JL, Beyers AD, Tse AGD, Mason DY: Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J Immunol 150:5429-5435, 1993[Abstract]
  45. Kariya K, Konno A, Ishida T: Perforin-like immunoreactivity in four cases of lymphoma of large granular lymphocytes in the cat. Vet Pathol 34:156-159, 1997[Abstract]
  46. Khan G, Norton AJ, Slavin G: Epstein-Barr virus in angio-immunoblastic T-cell lymhoma. Histopathology 22:145-149, 1993[Medline]
  47. Kinoshita K, Kamihira S, Ikeda S, Yamada Y, Muta T, Kitamura T, Ichimaru M, Matsuo T: Clinical, hematologic and pathologic features of leukemic T-cell lymphoma. Cancer 50:1554-1562, 1982[CrossRef][Medline]
  48. Kiupel M, Teske E, Bostock D: Prognostic factors for treated canine malignant lymphoma. Vet pathol 36:292-300, 1999[Abstract]
  49. Knowles DM: Immunophenotypic and antigen receptor gene rearrangement analysis in T-cell neoplasia. Am J Pathol 134:761-785, 1989[Abstract]
  50. Konno A, Hashimoto Y, Kon Y, Sugimura M: Perforin-like immunoreactivity in feline globule leukocytes and their distribution. J Vet Med Sci 56:1101-1105, 1994[Medline]
  51. Ladiges WC, Keast M, Appelbaum F, Storb R: Phenotypic characterization of canine lymphoma using monoclonal antibodies and a microlymphocytotoxicity assay. Am J Vet Res 49:870-872, 1988[Medline]
  52. Lennert K, Feller CA: Histologie des Lymphomes Malins Non Hodgkiniens Selon la Classification de Kiel Actualisée. Doin, Paris, France 1991
  53. Lennert K, Mohri N, Stein H, Kaiserling E, Müller-Hermelink HK: Malignant lymphomas other than Hodgkin's disease. In: Handbuch der Speziellen Pathologischen Anatomie und Histologie, pp 1-833, Springer, Berlin, Heidelberg, Germany 1978
  54. MacEwen EG: Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Rev 9:125-135, 1990[CrossRef][Medline]
  55. MacKenzie JL, Fabre JW: Studies with a monoclonal antibody on the distribution of Thy-1 in the lymphoid and extracellular connective tissues of the dog. Transplantation 31:275-281, 1981[Medline]
  56. Madewell BR: Hematological and bone marrow cytological abnormalities in 75 dogs with malignant lymphomas. J Am Anim Hosp Assoc 22:235-240, 1986
  57. Magnol JP, Ghernati I, Marchal T, Chabanne L, Delverdier A, Fournel-Fleury C: Données cliniques, morphologiques et immunophénotypiques à partir de 10 observations de lymphome T cutanéo-muqueux épithéliotrope du chien (analogue au mycosis fongoïde). Intérêt d'un modèle animal de pathologie spontanée. Bull Acad Natl Med 180:449-462, 1996[Medline]
  58. Mason DY, Cordell JL, Tse AGD, Van Dongen JJM, Van Noesel CJM, Micklem K, Pulfort KA, Valensi F, Comans-Bitter WM, Borst J, Gatter KC: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol 147:2474-2482, 1991
  59. McDonough SP, Moore PF: Clinical, hematologic, and immunophenotypic characterization of canine large granular lymphocytosis. Vet pathol 37:637-646, 2000[Abstract/Free Full Text]
  60. Moore PF, Olivry T, Naydan D: Canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T cells. Am J Pathol 144:421-429, 1994[Abstract]
  61. Moore PF, Rossito PV, Danilenko DM: Canine leukocyte integrins: characterization of a CD18 homologue. Tissue antigens 36:211-220, 1990[Medline]
  62. Moore PF, Rossito PV, Danilenko DM, Wielenga JJ, Raff RF, Severns E: Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. Tissue Antigens 40:75-85, 1992[Medline]
  63. Moore PF, Schrenzel MD, Affolter VK, Olivry T, Naydan D: Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific b2 integrin molecules. Am J Pathol 148:1699-1708, 1996[Abstract]
  64. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, Gosselin B, Bauters F, Gisselbrecht C: Prognosis and treatment of lymphoblastic lymphoma in adults. A report on 80 patients. J Clin Oncol 10:1078-1085, 1992[Abstract]
  65. Morgan G, Vornanen M, Puitinen J, Naukkarinen A, Brincker H, Olsen J, Coeburgh JW, Vrints LW, Clayden D, McNally R, Jack A, Carli PM, Petrella T, Tomino R, D'Lollo S, Barchielli A, Cartwright R: On behalf of the biomed study group: Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Ann Oncol 8:(Suppl 2) S49-S54, 1997
  66. Nathwani BN, Diamond LW, Winberg CD, Kim H, Bearman RM, Glick JH, Jones SE, Gams RA, Nissen Ni, Rappaport H: Lymphoblastic lymphoma. A clinicopathologic study of 95 patients. Cancer 48:2347-2357, 1981[CrossRef][Medline]
  67. National Cancer Institute: The non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982[CrossRef][Medline]
  68. Onions D: RNA-dependent DNA polymerase activity in canine lymphosarcoma. Eur J Cancer 16:345-350, 1980
  69. Owen LN, Bostock DE, Betton GR, Onions DE, Holmes J, Yoxall A, Gorman N: The role of spontaneous canine tumours in the evaluation of the etiology and therapy of human cancer. J Small Anim Pract 16:155-162, 1975[Medline]
  70. Parodi A, Wyers M, Paris J: Incidence of canine lymphoid leukosis. Age, sex and breed distribution: results of a necropsic survey. Proc 3rd Int Symp Comp Leukemia Res, Paris 1967, pp 263-267, Bibl Haemat 31. Karger, Basel, Switzerland/New York, NY 1968
  71. Parodi AL, Dargent F, Crespeau F: Histological classification of canine malignant lymphomas. J Vet Med A 35:178-192, 1988
  72. Pelt RW, van Connor GH: Clinicopathologic survey of malignant lymphoma in the dog. J Am Vet Med Assoc 152:976-989, 1968[Medline]
  73. Pierrepoint CG: Possible benefits to veterinary medicine of considering the dog as a model for human cancer. J Small Anim Pract 26:43-47, 1985
  74. Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E: From the R.E.A.L. classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Annals Oncol 9:607-612, 1998[Free Full Text]
  75. Poiesz B, Ruscetti F, Gazdar A: Detection and isolation of type C retrovirus particles from fresh and cultured lymphcytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415-7419, 1980[Abstract/Free Full Text]
  76. Priester WA: Canine lymphoma: relative risk in the boxer breed. J Natl Cancer Inst 39:833-845, 1967
  77. Priester WA, McKay FW: The occurrence of tumors in domestic animals. Bethseda, Maryland, NC1 Monogr 54:166, 1980
  78. Rappaport H: Tumors of the haematopoietic system. In: Atlas of Tumor Pathology, Section 3, fasc. 8, pp 442, Armed Forces Inst Pathol, Washington, DC 1966
  79. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD: Transformation of cutaneous T-cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol 132:265-277, 1988[Abstract]
  80. Sandusky GE, Horton PJ, Wightman KA: Use of monoclonal antibodies to human lymphocytes to identify lymphocyte subsets in lymph nodes of the rhesus monkey and dog. J med Primatol 15:441-451, 1986[Medline]
  81. Solal-Celigny Ph, Brousse N, Fermé Ch, Gisselbrecht Ch, Reyes F, Coiffier B: Lymphomes, Lymphomes non Hodgkiniens—Maladie de Hodgkin, 3ème ed. Frison-Roche, Paris, France 1997
  82. Squire RA, Bush M, Melby EC, Neeley LM, Yarbrough B: Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy. J Natl Cancer Inst 56:565-574, 1973
  83. Strandstrom HV, Bowen JM: Canine leukemia-lymphoma complex: a model for human hematopoietic malignancies. In: Advances in Comparative Leukemic Research, ed. Yohn DS, Blakerslee Jr, pp 447-450, Elsevier, New York, NY 1998
  84. Teske E: Canine malignant lymphoma: a review and comparison with human non-Hondgkin's lymphomas. Vet Quat 4:209-219, 1994
  85. Teske E, Wisman P, Moore PF, Van Heerde P: Histologic classification and immuno-phenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Exp Haematol 22:1179-1187, 1994[Medline]
  86. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification on non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997[Abstract/Free Full Text]
  87. Tokunaga M, Sato F: Non-Hodgkin's lymphomas in a southern prefecture in Japan: an analysis of 715 cases. Cancer 46:1231-1239, 1980[CrossRef][Medline]
  88. Tomley FM, Armstrong SJ, Mahy BWJ, Owen LN: Reverse transcriptase activity and particles of retroviral density in cultured canine lymphosarcoma supernatants. Br J Cancer 47:277-284, 1983[Medline]
  89. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchimo H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50:481, 1977[Free Full Text]
  90. Valli VE: Techniques in veterinary cytopathology. Semin Vet Med Surg (Small Anim) 3:85-93, 1988
  91. Vernau W, Moore PF: An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol 69:(2–4) 145-164, 1999[CrossRef][Medline]
  92. Weir EC, Greenlee P, Matus R, Brooks M, Morris C, Insogna K: Hypercalcemia in canine lymphosarcoma is associated with the T-cell subtype and with secretion of a PTH-like factor. J Bone Miner Res 3:S106, [Abstract] 1988
  93. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet ii:575-577, 1993
  94. Yamada Y: Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood 61:192-199, 1983[Abstract/Free Full Text]
  95. Zhou XG, Hamilton-Dutoit SJ, Yan QH, Pallesen G: High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma. Histopathology 24:115-122, 1994[Medline]
  96. Zucca E, Roggero E, Pileri S: B-cell lymphoma of MALT type. A review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br J Haematol 100:3-14, 1998[CrossRef][Medline]
Request reprints from Corinne Fournel-Fleury, Ecole Nationale Vétérinaire de Lyon, Laboratoire d'Hématologie-Cytologie-Immunopathologie, Service de Médecine, 1, av. Bourgelat BP 83-69280, Marcy-L'Etoile (France). E-mail: c.fournel{at}vet-lyon.fr.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 jvdiHome page
C. Thuilliez, D. Watrelot-Virieux, F. Chanut, C. Fournel-Fleury, F. Ponce, and T. Marchal
Presumed primary muscular lymphoma in a dog
J Vet Diagn Invest, November 1, 2008; 20(6): 824 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Animal Hospital AssociationHome page
S. Tzannes, P. Ibarrola, D. J. Batchelor, R. D. Burrow, and L. Blackwood
Use of Recombinant Human Interferon Alpha-2a in the Management of a Dog With Epitheliotropic Lymphoma
J. Am. Anim. Hosp. Assoc., September 1, 2008; 44(5): 276 - 282.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
V. E. Valli, W. Vernau, L.-P de Lorimier, P. S. Graham, and P. F. Moore
Canine Indolent Nodular Lymphoma
Vet. Pathol., May 1, 2006; 43(3): 241 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
C. M. Jubala, J. W. Wojcieszyn, V. E. O. Valli, D. M. Getzy, S. P. Fosmire, D. Coffey, D. Bellgrau, and J. F. Modiano
CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma
Vet. Pathol., July 1, 2005; 42(4): 468 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
K. A. Coyle and H. Steinberg
Characterization of Lymphocytes in Canine Gastrointestinal Lymphoma
Vet. Pathol., March 1, 2004; 41(2): 141 - 146.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fournel-Fleury, C.
Right arrow Articles by Magnol, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fournel-Fleury, C.
Right arrow Articles by Magnol, J. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS